From genes to cognition in tuberous sclerosis: Implications for mTOR inhibitor-based treatment approaches

Neuropharmacology

Volumn 68, Issue , 2013, Pages 97-105

  Ehninger, Dan ^a  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Autism; Cognition; Epilepsy; mTOR; Rapamycin; TSC; Tuberous sclerosis

Indexed keywords

EVEROLIMUS; HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1 INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; TUBERIN; UNCLASSIFIED DRUG; VIGABATRIN;

ASTROCYTE; ASTROGLIAL ABNORMALITY; AUTOPHAGY; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DISEASE ASSOCIATION; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG PENETRATION; ENDOPLASMIC RETICULUM STRESS; EPILEPSY; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; INTELLECTUAL IMPAIRMENT; MENTAL DISEASE; MOLECULAR PATHOLOGY; MYELIN DEFICIENCY; MYELINATION; MYELINATION DEFECT; NERVE CELL NECROSIS; NERVOUS SYSTEM FUNCTION; NEURAL CONNECTIVITY; NEUROBIOLOGY; NEUROLOGIC DISEASE; NEURONAL DYSFUNCTION; NEUROPATHOLOGY; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; SEIZURE; SINGLE DRUG DOSE; SYMPTOMATOLOGY; TREATMENT DURATION; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS; WHITE MATTER LESION;

ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; HUMANS; PHENOTYPE; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

EID: 84875210974     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.05.015     Document Type: Review

References (152)

1. S. Anderl, M. Freeland, D.J. Kwiatkowski, and J. Goto Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex Hum. Mol. Genet. 20 2011 4597 4604
2. P.A. Arguello, and J.A. Gogos A signaling pathway AKTing up in schizophrenia J. Clin. Invest. 118 2008 2018 2021
3. B.D. Auerbach, E.K. Osterweil, and M.F. Bear Mutations causing syndromic autism define an axis of synaptic pathophysiology Nature 480 2011 63 68
4. S. Banerjee, S.M. Gianino, F. Gao, U. Christians, and D.H. Gutmann Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes Mol. Cancer Ther. 10 2011 279 291
5. H.S. Bateup, K.T. Takasaki, J.L. Saulnier, C.L. Denefrio, and B.L. Sabatini Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function J. Neurosci. 31 2011 8862 8869
6. G. Benvenuto, S. Li, S.J. Brown, R. Braverman, W.C. Vass, J.P. Cheadle, D.J. Halley, J.R. Sampson, R. Wienecke, and J.E. DeClue The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination Oncogene 19 2000 6306 6316
7. Z. Berger, B. Ravikumar, F.M. Menzies, L.G. Oroz, B.R. Underwood, M.N. Pangalos, I. Schmitt, U. Wullner, B.O. Evert, C.J. O'Kane, and D.C. Rubinsztein Rapamycin alleviates toxicity of different aggregate-prone proteins Hum. Mol. Genet. 15 2006 433 442
8. J.J. Bissler, F.X. McCormack, L.R. Young, J.M. Elwing, G. Chuck, J.M. Leonard, V.J. Schmithorst, T. Laor, A.S. Brody, J. Bean, S. Salisbury, and D.N. Franz Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis N. Engl. J. Med. 358 2008 140 151
9. K. Boer, D. Troost, F. Jansen, M. Nellist, A.M. van den Ouweland, J.J. Geurts, W.G. Spliet, P. Crino, and E. Aronica Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex Neuropathology 28 2008 577 590
10. P.F. Bolton, R.J. Park, J.N. Higgins, P.D. Griffiths, and A. Pickles Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex Brain 125 2002 1247 1255
11. D. Bourneville Sclerose tubereuse des circonvolutions cerebrales: Idiotie et epilepsie hemiplegique Arch. Neurol. (Paris) 1 1880 81 91
12. M.G. Butler, M.J. Dasouki, X.P. Zhou, Z. Talebizadeh, M. Brown, T.N. Takahashi, J.H. Miles, C.H. Wang, R. Stratton, R. Pilarski, and C. Eng Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations J. Med. Genet. 42 2005 318 321
13. A. Caccamo, S. Majumder, A. Richardson, R. Strong, and S. Oddo Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments J. Biol. Chem. 285 2010 13107 13120
14. D.B. Campbell, J.S. Sutcliffe, P.J. Ebert, R. Militerni, C. Bravaccio, S. Trillo, M. Elia, C. Schneider, R. Melmed, R. Sacco, A.M. Persico, and P. Levitt A genetic variant that disrupts MET transcription is associated with autism Proc. Natl. Acad. Sci. U. S. A. 103 2006 16834 16839
15. R.P. Carson, D.L. Van Nielen, P.A. Winzenburger, and K.C. Ess Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin Neurobiol. Dis. 45 2012 369 380
16. I. Chevere-Torres, H. Kaphzan, A. Bhattacharya, A. Kang, J.M. Maki, M.J. Gambello, J.L. Arbiser, E. Santini, and E. Klann Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the DeltaRG mouse model of tuberous sclerosis complex Neurobiol. Dis. 45 2012 1101 1110
17. I. Chevere-Torres, J.M. Maki, E. Santini, and E. Klann Impaired social interactions and motor learning skills in tuberous sclerosis complex model mice expressing a dominant/negative form of tuberin Neurobiol. Dis. 45 2012 156 164
18. Y.J. Choi, A. Di Nardo, I. Kramvis, L. Meikle, D.J. Kwiatkowski, M. Sahin, and X. He Tuberous sclerosis complex proteins control axon formation Genes Dev. 22 2008 2485 2495
19. H. Chong-Kopera, K. Inoki, Y. Li, T. Zhu, F.R. Garcia-Gonzalo, J.L. Rosa, and K.L. Guan TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase J. Biol. Chem. 281 2006 8313 8316
20. D.K. Chow, M. Groszer, M. Pribadi, M. Machniki, S.T. Carmichael, X. Liu, and J.T. Trachtenberg Laminar and compartmental regulation of dendritic growth in mature cortex Nat. Neurosci. 12 2009 116 118
21. M. Costa-Mattioli, W.S. Sossin, E. Klann, and N. Sonenberg Translational control of long-lasting synaptic plasticity and memory Neuron 61 2009 10 26
22. P.B. Crino, K.L. Nathanson, and E.P. Henske The tuberous sclerosis complex N. Engl. J. Med. 355 2006 1345 1356
23. P.B. Crino, E. Aronica, G. Baltuch, and K.L. Nathanson Biallelic TSC gene inactivation in tuberous sclerosis complex Neurology 74 2010 1716 1723
24. P. Curatolo, R. Bombardieri, and S. Jozwiak Tuberous sclerosis Lancet 372 2008 657 668
25. R. Cusmai, R. Moavero, R. Bombardieri, F. Vigevano, and P. Curatolo Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis Epilepsy Behav. 22 2011 735 739
26. S.L. Dabora, P. Roberts, A. Nieto, R. Perez, S. Jozwiak, D. Franz, J. Bissler, E.A. Thiele, K. Sims, and D.J. Kwiatkowski Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients Am. J. Hum. Genet. 71 2002 750 758
27. D.M. Davies, P.J. de Vries, S.R. Johnson, D.L. McCartney, J.A. Cox, A.L. Serra, P.C. Watson, C.J. Howe, T. Doyle, K. Pointon, J.J. Cross, A.E. Tattersfield, J.C. Kingswood, and J.R. Sampson Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial Clin. Cancer Res. 17 2011 4071 4081
28. P.J. de Vries, and C.J. Howe The tuberous sclerosis complex proteins-a GRIPP on cognition and neurodevelopment Trends Mol. Med. 13 2007 319 326
29. P.J. de Vries, and P.A. Prather The tuberous sclerosis complex N. Engl. J. Med. 356 2007 92 Author reply 93-94
30. P.J. de Vries, A. Hunt, and P.F. Bolton The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families Eur. Child. Adolesc. Psychiatry 16 2007 16 24
31. P. de Vries, A. Humphrey, D. McCartney, P. Prather, P. Bolton, and A. Hunt Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis Eur. Child. Adolesc. Psychiatry 14 2005 183 190
32. P.J. de Vries, J. Gardiner, and P.F. Bolton Neuropsychological attention deficits in tuberous sclerosis complex (TSC) Am. J. Med. Genet. A 149A 2009 387 395
33. B. Dehay, J. Bove, N. Rodriguez-Muela, C. Perier, A. Recasens, P. Boya, and M. Vila Pathogenic lysosomal depletion in Parkinson's disease J. Neurosci. 30 2010 12535 12544
34. A. Di Nardo, I. Kramvis, N. Cho, A. Sadowski, L. Meikle, D.J. Kwiatkowski, and M. Sahin Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner J. Neurosci. 29 2009 5926 5937
35. D. Ehninger, and A.J. Silva Genetics and neuropsychiatric disorders: treatment during adulthood Nat. Med. 15 2009 849 850
36. D. Ehninger, and A.J. Silva Increased levels of anxiety-related behaviors in a Tsc2 dominant negative transgenic mouse model of tuberous sclerosis Behav. Genet. 41 2011 357 363
37. D. Ehninger, and A.J. Silva Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders Trends Mol. Med. 17 2011 78 87
38. D. Ehninger, S. Han, C. Shilyansky, Y. Zhou, W. Li, D.J. Kwiatkowski, V. Ramesh, and A.J. Silva Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis Nat. Med. 14 2008 843 848
39. D. Ehninger, P.J. de Vries, and A.J. Silva From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis J. Intellect. Disabil. Res. 53 2009 838 851
40. D. Ehninger, Y. Sano, P.J. de Vries, K. Dies, D. Franz, D.H. Geschwind, M. Kaur, Y.S. Lee, W. Li, J.K. Lowe, J.A. Nakagawa, M. Sahin, K. Smith, V. Whittemore, and A.J. Silva Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice Mol. Psychiatry 17 2012 62 70
41. European Chromosome 16 Tuberous Sclerosis Consortium Identification and characterization of the tuberous sclerosis gene on chromosome 16 Cell 75 1993 1305 1315
42. E. Fombonne Epidemiological surveys of autism and other pervasive developmental disorders: an update J. Autism Dev. Disord. 33 2003 365 382
43. D.N. Franz, J. Leonard, C. Tudor, G. Chuck, M. Care, G. Sethuraman, A. Dinopoulos, G. Thomas, and K.R. Crone Rapamycin causes regression of astrocytomas in tuberous sclerosis complex Ann. Neurol. 59 2006 490 498
44. C. Fu, B. Cawthon, W. Clinkscales, A. Bruce, P. Winzenburger, and K.C. Ess GABAergic Interneuron Development and Function Is Modulated by the Tsc1 Gene 2011 Cereb Cortex
45. J.N. Gelinas, J.L. Banko, L. Hou, N. Sonenberg, E.J. Weeber, E. Klann, and P.V. Nguyen ERK and mTOR signaling couple beta-adrenergic receptors to translation initiation machinery to gate induction of protein synthesis-dependent long-term potentiation J. Biol. Chem. 282 2007 27527 27535
46. I.C. Gillberg, C. Gillberg, and G. Ahlsen Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study Dev. Med. Child. Neurol. 36 1994 50 56
47. A.C. Gingras, B. Raught, and N. Sonenberg mTOR signaling to translation Curr. Top. Microbiol. Immunol. 279 2004 169 197
48. R. Gong, C.S. Park, N.R. Abbassi, and S.J. Tang Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons J. Biol. Chem. 281 2006 18802 18815
49. S.M. Goorden, G.M. van Woerden, L. van der Weerd, J.P. Cheadle, and Y. Elgersma Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures Ann. Neurol. 62 2007 648 655
50. J. Goto, D.M. Talos, P. Klein, W. Qin, Y.I. Chekaluk, S. Anderl, I.A. Malinowska, A. Di Nardo, R.T. Bronson, J.A. Chan, H.V. Vinters, S.G. Kernie, F.E. Jensen, M. Sahin, and D.J. Kwiatkowski Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex Proc. Natl. Acad. Sci. U. S. A. 108 2011 E1070 E1079
51. B. Govindarajan, D.J. Brat, M. Csete, W.D. Martin, E. Murad, K. Litani, C. Cohen, F. Cerimele, M. Nunnelley, B. Lefkove, T. Yamamoto, C. Lee, and J.L. Arbiser Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain J. Biol. Chem. 280 2005 5870 5874
52. D.A. Guertin, and D.M. Sabatini The pharmacology of mTOR inhibition Sci. Signal. 2 2009 pe24
53. T. Hara, K. Nakamura, M. Matsui, A. Yamamoto, Y. Nakahara, R. Suzuki-Migishima, M. Yokoyama, K. Mishima, I. Saito, H. Okano, and N. Mizushima Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice Nature 441 2006 885 889
54. L.S. Harrington, G.M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield, H. Rebholz, J. Barnett, N.R. Leslie, S. Cheng, P.R. Shepherd, I. Gout, C.P. Downes, and R.F. Lamb The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins J. Cell Biol. 166 2004 213 223
55. J.E. Harrison, F.J. O'Callaghan, E. Hancock, J.P. Osborne, and P.F. Bolton Cognitive deficits in normally intelligent patients with tuberous sclerosis Am. J. Med. Genet. 88 1999 642 646
56. K.E. Hentges, B. Sirry, A.C. Gingeras, D. Sarbassov, N. Sonenberg, D. Sabatini, and A.S. Peterson FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse Proc. Natl. Acad. Sci. U. S. A. 98 2001 13796 13801
57. C.A. Hoeffer, E. Sanchez, R.J. Hagerman, Y. Mu, D.V. Nguyen, H. Wong, A.M. Whelan, R.S. Zukin, E. Klann, and F. Tassone Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome Genes Brain Behav. 2012
58. J. Huang, and B.D. Manning A complex interplay between Akt, TSC2 and the two mTOR complexes Biochem. Soc. Trans. 37 2009 217 222
59. J. Huang, C.C. Dibble, M. Matsuzaki, and B.D. Manning The TSC1-TSC2 complex is required for proper activation of mTOR complex 2 Mol. Cell Biol. 28 2008 4104 4115
60. A. Hunt, and J. Dennis Psychiatric disorder among children with tuberous sclerosis Dev. Med. Child. Neurol. 29 1987 190 198
61. K. Inoki, Y. Li, T. Zhu, J. Wu, and K.L. Guan TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat. Cell Biol. 4 2002 648 657
62. K. Inoki, T. Zhu, and K.L. Guan TSC2 mediates cellular energy response to control cell growth and survival Cell 115 2003 577 590
63. L.A. Jansen, E.J. Uhlmann, P.B. Crino, D.H. Gutmann, and M. Wong Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes Epilepsia 46 2005 1871 1880
64. J. Jaworski, S. Spangler, D.P. Seeburg, C.C. Hoogenraad, and M. Sheng Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt- mammalian target of rapamycin pathway J. Neurosci. 25 2005 11300 11312
65. S.S. Jeste, M. Sahin, P. Bolton, G.B. Ploubidis, and A. Humphrey Characterization of autism in young children with tuberous sclerosis complex J. Child. Neurol. 23 2008 520 525
66. C.M. Johannessen, E.E. Reczek, M.F. James, H. Brems, E. Legius, and K. Cichowski The NF1 tumor suppressor critically regulates TSC2 and mTOR Proc. Natl. Acad. Sci. U. S. A. 102 2005 8573 8578
67. C. Joinson, F.J. O'Callaghan, J.P. Osborne, C. Martyn, T. Harris, and P.F. Bolton Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex Psychol. Med. 33 2003 335 344
68. J. Jozwiak, S. Jozwiak, and P. Wlodarski Possible mechanisms of disease development in tuberous sclerosis Lancet Oncol. 9 2008 73 79
69. S. Jozwiak, K. Kotulska, D. Domanska-Pakiela, B. Lojszczyk, M. Syczewska, D. Chmielewski, D. Dunin-Wasowicz, T. Kmiec, J. Szymkiewicz-Dangel, M. Kornacka, W. Kawalec, D. Kuczynski, J. Borkowska, K. Tomaszek, E. Jurkiewicz, and M. Respondek-Liberska Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex Eur. J. Paediatr. Neurol. 15 2011 424 431
70. P. Kapahi, D. Chen, A.N. Rogers, S.D. Katewa, P.W. Li, E.L. Thomas, and L. Kockel With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging Cell Metab. 11 2010 453 465
71. H. Katagiri, K. Tanaka, and T. Manabe Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction Eur. J. Neurosci. 14 2001 547 553
72. R.J. Kelleher 3rd, A. Govindarajan, H.Y. Jung, H. Kang, and S. Tonegawa Translational control by MAPK signaling in long-term synaptic plasticity and memory Cell 116 2004 467 479
73. Y. Kikuchi, A. Sudo, H. Mitani, and O. Hino Presence of a modifier gene(s) affecting early renal carcinogenesis in the Tsc2 mutant (Eker) rat model Int. J. Oncol. 24 2004 75 80
74. E. Klann, and T.E. Dever Biochemical mechanisms for translational regulation in synaptic plasticity Nat. Rev. Neurosci. 5 2004 931 942
75. M. Komatsu, S. Waguri, T. Chiba, S. Murata, J. Iwata, I. Tanida, T. Ueno, M. Koike, Y. Uchiyama, E. Kominami, and K. Tanaka Loss of autophagy in the central nervous system causes neurodegeneration in mice Nature 441 2006 880 884
76. M.L. Krishnan, O. Commowick, S.S. Jeste, N. Weisenfeld, A. Hans, M.C. Gregas, M. Sahin, and S.K. Warfield Diffusion features of white matter in tuberous sclerosis with tractography Pediatr. Neurol. 42 2010 101 106
77. D.A. Krueger, M.M. Care, K. Holland, K. Agricola, C. Tudor, P. Mangeshkar, K.A. Wilson, A. Byars, T. Sahmoud, and D.N. Franz Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N. Engl. J. Med. 363 2010 1801 1811
78. V. Kumar, M.X. Zhang, M.W. Swank, J. Kunz, and G.Y. Wu Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways J. Neurosci. 25 2005 11288 11299
79. C.H. Kwon, X. Zhu, J. Zhang, and S.J. Baker mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo Proc. Natl. Acad. Sci. U. S. A. 100 2003 12923 12928
80. W.S. Lai, B. Xu, K.G. Westphal, M. Paterlini, B. Olivier, P. Pavlidis, M. Karayiorgou, and J.A. Gogos Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning Proc. Natl. Acad. Sci. U. S. A. 103 2006 16906 16911
81. R.F. Lamb, C. Roy, T.J. Diefenbach, H.V. Vinters, M.W. Johnson, D.G. Jay, and A. Hall The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho Nat. Cell Biol. 2 2000 281 287
82. G. Lenz, and J. Avruch Glutamatergic regulation of the p70S6 kinase in primary mouse neurons J. Biol. Chem. 280 2005 38121 38124
83. J.C. Lewis, H.V. Thomas, K.C. Murphy, and J.R. Sampson Genotype and psychological phenotype in tuberous sclerosis J. Med. Genet. 41 2004 203 207
84. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, M. Iwata, X.Y. Li, G. Aghajanian, and R.S. Duman mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
85. C.H. Lin, S.H. Yeh, K.T. Lu, T.H. Leu, W.C. Chang, and P.W. Gean A role for the PI-3 kinase signaling pathway in fear conditioning and synaptic plasticity in the amygdala Neuron 31 2001 841 851
86. L. Ma, Z. Chen, H. Erdjument-Bromage, P. Tempst, and P.P. Pandolfi Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis Cell 121 2005 179 193
87. B.D. Manning, A.R. Tee, M.N. Logsdon, J. Blenis, and L.C. Cantley Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway Mol. Cell 10 2002 151 162
88. L. Meikle, D.M. Talos, H. Onda, K. Pollizzi, A. Rotenberg, M. Sahin, F.E. Jensen, and D.J. Kwiatkowski A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival J. Neurosci. 27 2007 5546 5558
89. L. Meikle, K. Pollizzi, A. Egnor, I. Kramvis, H. Lane, M. Sahin, and D.J. Kwiatkowski Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function J. Neurosci. 28 2008 5422 5432
90. D.A. Muzykewicz, P. Newberry, N. Danforth, E.F. Halpern, and E.A. Thiele Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex Epilepsy Behav. 11 2007 506 513
91. M. Neves-Pereira, B. Muller, D. Massie, J.H. Williams, P.C. O'Brien, A. Hughes, S.B. Shen, D.S. Clair, and Z. Miedzybrodzka Deregulation of EIF4E: a novel mechanism for autism J. Med. Genet. 46 2009 759 765
92. D. Nie, A. Di Nardo, J.M. Han, H. Baharanyi, I. Kramvis, T. Huynh, S. Dabora, S. Codeluppi, P.P. Pandolfi, E.B. Pasquale, and M. Sahin Tsc2-Rheb signaling regulates EphA-mediated axon guidance Nat. Neurosci. 13 2010 163 172
93. A.L. Numis, P. Major, M.A. Montenegro, D.A. Muzykewicz, M.B. Pulsifer, and E.A. Thiele Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex Neurology 76 2011 981 987
94. F.J. O'Callaghan, T. Harris, C. Joinson, P. Bolton, M. Noakes, D. Presdee, S. Renowden, A. Shiell, C.N. Martyn, and J.P. Osborne The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex Arch. Dis. Child. 89 2004 530 533
95. H. Onda, A. Lueck, P.W. Marks, H.B. Warren, and D.J. Kwiatkowski Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background J. Clin. Invest. 104 1999 687 695
96. J.P. Osborne, A. Fryer, and D. Webb Epidemiology of tuberous sclerosis Ann. N. Y. Acad. Sci. 615 1991 125 127
97. N. Oshiro, K. Yoshino, S. Hidayat, C. Tokunaga, K. Hara, S. Eguchi, J. Avruch, and K. Yonezawa Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function Genes Cells 9 2004 359 366
98. P. Prather, and P.J. de Vries Behavioral and cognitive aspects of tuberous sclerosis complex J. Child. Neurol. 19 2004 666 674
99. K.F. Raab-Graham, P.C. Haddick, Y.N. Jan, and L.Y. Jan Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites Science 314 2006 144 148
100. B. Ravikumar, C. Vacher, Z. Berger, J.E. Davies, S. Luo, L.G. Oroz, F. Scaravilli, D.F. Easton, R. Duden, C.J. O'Kane, and D.C. Rubinsztein Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease Nat. Genet. 36 2004 585 595
101. B. Ravikumar, Z. Berger, C. Vacher, C.J. O'Kane, and D.C. Rubinsztein Rapamycin pre-treatment protects against apoptosis Hum. Mol. Genet. 15 2006 1209 1216
102. R.M. Reith, S. Way, J. McKenna 3rd, K. Haines, and M.J. Gambello Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration Neurobiol. Dis. 43 2011 113 122
103. K. Ridler, J. Suckling, N. Higgins, P. Bolton, and E. Bullmore Standardized whole brain mapping of tubers and subependymal nodules in tuberous sclerosis complex J. Child. Neurol. 19 2004 658 665
104. K. Ridler, J. Suckling, N.J. Higgins, P.J. de Vries, C.M. Stephenson, P.F. Bolton, and E.T. Bullmore Neuroanatomical correlates of memory deficits in tuberous sclerosis complex Cereb. Cortex 17 2007 261 271
105. D.C. Rubinsztein The roles of intracellular protein-degradation pathways in neurodegeneration Nature 443 2006 780 786
106. O. Sancak, M. Nellist, M. Goedbloed, P. Elfferich, C. Wouters, A. Maat-Kievit, B. Zonnenberg, S. Verhoef, D. Halley, and A. van den Ouweland Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex Eur. J. Hum. Genet. 13 2005 731 741
107. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
108. D.D. Sarbassov, S.M. Ali, S. Sengupta, J.H. Sheen, P.P. Hsu, A.F. Bagley, A.L. Markhard, and D.M. Sabatini Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol. Cell 22 2006 159 168
109. L.J. Saucedo, X. Gao, D.A. Chiarelli, L. Li, D. Pan, and B.A. Edgar Rheb promotes cell growth as a component of the insulin/TOR signalling network Nat. Cell Biol. 5 2003 566 571
110. G.M. Schratt, E.A. Nigh, W.G. Chen, L. Hu, and M.E. Greenberg BDNF regulates the translation of a select group of mRNAs by a mammalian target of rapamycin-phosphatidylinositol 3-kinase-dependent pathway during neuronal development J. Neurosci. 24 2004 7366 7377
111. O.J. Shah, Z. Wang, and T. Hunter Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies Curr. Biol. 14 2004 1650 1656
112. A. Sharma, C.A. Hoeffer, Y. Takayasu, T. Miyawaki, S.M. McBride, E. Klann, and R.S. Zukin Dysregulation of mTOR signaling in fragile X syndrome J. Neurosci. 30 2010 694 702
113. S.L. Smalley, P.E. Tanguay, M. Smith, and G. Gutierrez Autism and tuberous sclerosis J. Autism Dev. Disord. 22 1992 339 355
114. S.L. Smalley Autism and tuberous sclerosis J. Autism Dev. Disord. 28 1998 407 414
115. P. Spilman, N. Podlutskaya, M.J. Hart, J. Debnath, O. Gorostiza, D. Bredesen, A. Richardson, R. Strong, and V. Galvan Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease PLoS One 5 2010 e9979
116. H. Stocker, T. Radimerski, B. Schindelholz, F. Wittwer, P. Belawat, P. Daram, S. Breuer, G. Thomas, and E. Hafen Rheb is an essential regulator of S6K in controlling cell growth in Drosophila Nat. Cell Biol. 5 2003 559 565
117. M.A. Sutton, and E.M. Schuman Local translational control in dendrites and its role in long-term synaptic plasticity J. Neurobiol. 64 2005 116 131
118. L. Swiech, M. Perycz, A. Malik, and J. Jaworski Role of mTOR in physiology and pathology of the nervous system Biochim. Biophys. Acta 1784 2008 116 132
119. N. Takei, N. Inamura, M. Kawamura, H. Namba, K. Hara, K. Yonezawa, and H. Nawa Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites J. Neurosci. 24 2004 9760 9769
120. S.J. Tang, G. Reis, H. Kang, A.C. Gingras, N. Sonenberg, and E.M. Schuman A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus Proc. Natl. Acad. Sci. U. S. A. 99 2002 467 472
121. G. Tang, M. Cotrina, and D. Sulzer Impaired Autophagy and Dendritic Spine Malformation in TSC Deficient Mice 2010 Annual Meeting of the Society for Neuroscience 870.872/AA812 p.
122. S.F. Tavazoie, V.A. Alvarez, D.A. Ridenour, D.J. Kwiatkowski, and B.L. Sabatini Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2 Nat. Neurosci. 8 2005 1727 1734
123. A.R. Tee, D.C. Fingar, B.D. Manning, D.J. Kwiatkowski, L.C. Cantley, and J. Blenis Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling Proc. Natl. Acad. Sci. U. S. A. 99 2002 13571 13576
124. A.R. Tee, R. Anjum, and J. Blenis Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin J. Biol. Chem. 278 2003 37288 37296
125. K.M. Tierney, D.L. McCartney, J.R. Serfontein, and P.J. de Vries Neuropsychological attention skills and related behaviours in adults with tuberous sclerosis complex Behav. Genet. 41 2011 437 444
126. J.M. Tillema, J.L. Leach, D.A. Krueger, and D.N. Franz Everolimus alters white matter diffusion in tuberous sclerosis complex Neurology 78 2012 526 531
127. E.J. Uhlmann, M. Wong, R.L. Baldwin, M.L. Bajenaru, H. Onda, D.J. Kwiatkowski, K. Yamada, and D.H. Gutmann Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures Ann. Neurol. 52 2002 285 296
128. M. van Slegtenhorst, R. de Hoogt, C. Hermans, M. Nellist, B. Janssen, S. Verhoef, D. Lindhout, A. van den Ouweland, D. Halley, J. Young, M. Burley, S. Jeremiah, K. Woodward, J. Nahmias, M. Fox, R. Ekong, J. Osborne, J. Wolfe, S. Povey, R.G. Snell, J.P. Cheadle, A.C. Jones, M. Tachataki, D. Ravine, J.R. Sampson, M.P. Reeve, P. Richardson, F. Wilmer, C. Munro, T.L. Hawkins, T. Sepp, J.B. Ali, S. Ward, A.J. Green, J.R. Yates, J. Kwiatkowska, E.P. Henske, M.P. Short, J.H. Haines, S. Jozwiak, and D.J. Kwiatkowski Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34 Science 277 1997 805 808
129. P.W. Vanderklish, and G.M. Edelman Differential translation and fragile X syndrome Genes Brain Behav. 4 2005 360 384
130. V. Veverka, T. Crabbe, I. Bird, G. Lennie, F.W. Muskett, R.J. Taylor, and M.D. Carr Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR Oncogene 27 2008 585 595
131. H. Vogt Zur Pathologie und pathologischen Anatomie der verschiedenen Idiotieformen Monatsschr. Psychiatr. Neurol. 24 1908 106 150
132. C. von der Brelie, R. Waltereit, L. Zhang, H. Beck, and T. Kirschstein Impaired synaptic plasticity in a rat model of tuberous sclerosis Eur. J. Neurosci. 23 2006 686 692
133. F. von Recklinghausen Ein Herz von einem Neugeborene welches mehrere theils nach aussen, theils nach den Höhlen prominirende Tumoren (Myomen) trug Monatsschr. Geburtsheilkd. 20 1862 1 2
134. R. Waltereit, H. Welzl, J. Dichgans, H.P. Lipp, W.J. Schmidt, and M. Weller Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis J. Neurochem. 96 2006 407 413
135. R. Waltereit, B. Japs, M. Schneider, P.J. de Vries, and D. Bartsch Epilepsy and Tsc2 haploinsufficiency lead to autistic-like social deficit behaviors in rats Behav. Genet. 41 2011 364 372
136. Y. Wang, M.F. Barbaro, and S.C. Baraban A role for the mTOR pathway in surface expression of AMPA receptors Neurosci. Lett. 401 2006 35 39
137. S.W. Way, J. McKenna 3rd, U. Mietzsch, R.M. Reith, H.C. Wu, and M.J. Gambello Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse Hum. Mol. Genet. 18 2009 1252 1265
138. D.W. Webb, A.E. Fryer, and J.P. Osborne Morbidity associated with tuberous sclerosis: a population study Dev. Med. Child. Neurol. 38 1996 146 155
139. R.J. White, and A.D. Sharrocks Coordinated control of the gene expression machinery Trends Genet. 26 2010 214 220
140. P.G. Williams, and J.H. Hersh Brief report: the association of neurofibromatosis type 1 and autism J. Autism Dev. Disord. 28 1998 567 571
141. E.B. Winterkorn, M.B. Pulsifer, and E.A. Thiele Cognitive prognosis of patients with tuberous sclerosis complex Neurology 68 2007 62 64
142. V. Wong, and P.L. Khong Tuberous sclerosis complex: correlation of magnetic resonance imaging (MRI) findings with comorbidities J. Child. Neurol. 21 2006 99 105
143. M. Wong, K.C. Ess, E.J. Uhlmann, L.A. Jansen, W. Li, P.B. Crino, S. Mennerick, K.A. Yamada, and D.H. Gutmann Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model Ann. Neurol. 54 2003 251 256
144. V. Wong Study of the relationship between tuberous sclerosis complex and autistic disorder J. Child. Neurol. 21 2006 199 204
145. L. Xu, L.H. Zeng, and M. Wong Impaired astrocytic gap junction coupling and potassium buffering in a mouse model of tuberous sclerosis complex Neurobiol. Dis. 34 2009 291 299
146. R.S. Yeung, H. Gu, M. Lee, and T.A. Dundon Genetic identification of a locus, Mot1, that affects renal tumor size in the rat Genomics 78 2001 108 112
147. D.I. Zafeiriou, A. Ververi, and E. Vargiami Childhood autism and associated comorbidities Brain Dev. 29 2007 257 272
148. L.H. Zeng, Y. Ouyang, V. Gazit, J.R. Cirrito, L.A. Jansen, K.C. Ess, K.A. Yamada, D.F. Wozniak, D.M. Holtzman, D.H. Gutmann, and M. Wong Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex Neurobiol. Dis. 28 2007 184 196
149. L.H. Zeng, L. Xu, D.H. Gutmann, and M. Wong Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex Ann. Neurol. 63 2008 444 453
150. L.H. Zeng, N.R. Rensing, B. Zhang, D.H. Gutmann, M.J. Gambello, and M. Wong Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex Hum. Mol. Genet. 20 2011 445 454
151. H. Zhang, G. Cicchetti, H. Onda, H.B. Koon, K. Asrican, N. Bajraszewski, F. Vazquez, C.L. Carpenter, and D.J. Kwiatkowski Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR J. Clin. Invest. 112 2003 1223 1233
152. Y. Zhang, X. Gao, L.J. Saucedo, B. Ru, B.A. Edgar, and D. Pan Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins Nat. Cell Biol. 5 2003 578 581